Protagenic Therapeutics Reports Key Corporate Events
Ticker: PTIXW · Form: 8-K · Filed: Aug 13, 2025 · CIK: 1022899
| Field | Detail |
|---|---|
| Company | Protagenic Therapeutics, Inc.\New (PTIXW) |
| Form Type | 8-K |
| Filed Date | Aug 13, 2025 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $8 million, $200,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, management-change, filing
Related Tickers: PTIX
TL;DR
Protagenic Therapeutics is shuffling execs and board members, plus some other corporate housekeeping. Watch PTIX.
AI Summary
Protagenic Therapeutics, Inc. filed an 8-K on August 13, 2025, reporting on several events that occurred on August 7, 2025. These include cost associated with exit or disposal activities, departure of directors or certain officers, election of directors, appointment of certain officers, compensatory arrangements of certain officers, and amendments to articles of incorporation or bylaws. The filing also notes a change in fiscal year and other events.
Why It Matters
This filing indicates significant corporate restructuring and personnel changes within Protagenic Therapeutics, which could impact its strategic direction and operational focus.
Risk Assessment
Risk Level: medium — Changes in directors, officers, and corporate structure can signal instability or strategic shifts that may affect the company's future performance.
Key Players & Entities
- Protagenic Therapeutics, Inc. (company) — Filer of the 8-K report
- PTIX (company) — Ticker symbol for Protagenic Therapeutics
FAQ
What specific reasons were cited for the departure of directors or officers?
The filing does not specify the reasons for the departure of directors or officers, only that these events occurred on August 7, 2025.
Were there any new appointments to the board or as officers?
Yes, the filing indicates the election of directors and the appointment of certain officers on August 7, 2025.
What kind of compensatory arrangements were made for officers?
The filing mentions compensatory arrangements of certain officers but does not provide specific details within the provided text.
What is the nature of the 'cost associated with exit or disposal activities'?
The filing lists this as an item of disclosure but does not provide specific details or dollar amounts for these costs in the provided text.
Has Protagenic Therapeutics changed its fiscal year end?
Yes, the filing indicates a change in fiscal year as one of the reported items.
Filing Stats: 998 words · 4 min read · ~3 pages · Grade level 13.6 · Accepted 2025-08-13 17:16:45
Key Financial Figures
- $8 million — zed operating expenses by approximately $8 million. The Company expects to incur one-time
- $200,000 — e annual fees not anticipated to exceed $200,000, to provide subject-matter expertise in
Filing Documents
- form8-k.htm (8-K) — 52KB
- 0001641172-25-023588.txt ( ) — 259KB
- ptix-20250807.xsd (EX-101.SCH) — 3KB
- ptix-20250807_def.xml (EX-101.DEF) — 26KB
- ptix-20250807_lab.xml (EX-101.LAB) — 36KB
- ptix-20250807_pre.xml (EX-101.PRE) — 25KB
- form8-k_htm.xml (XML) — 5KB
02
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On August 8, 2025, in connection with the Restructuring Plan, the Board a terminated the employment of (i) Barrett Evans as Chief Executive Officer and President and (ii) Colin Stott as Chief Operating Officer, in each case effective immediately. Messrs. Evans and Stott remain members of the Company's Board of Directors. Any severance or other compensatory agreements, if applicable, will be disclosed when determined. Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. On August 7, 2025, the Board approved a change in the Company's fiscal year-end from December 31 to March 31, effective immediately. The Company intends to file a transition report on Form 10-QT with the Securities and Exchange Commission for the transition period beginning April 1, 2025 and ending June 30, 2025. Item 8.01 Other Events. The Company provides the following operational update in connection with the Restructuring Plan: 1. Clinical focus . The Company will allocate available resources to efficiently execute the ongoing Phase 2 clinical trial of PT00114 (peptide analogue), which the Company currently expects to complete in approximately 9 to 12 months, subject to enrollment and other customary factors. 2. Preclinical programs . All preclinical programs originated with former Phytanix Bio (PHYX-001, PHYX-002, PHYX-003, PHYX-004, and PHYX-005) have been paused. The Company will actively pursue strategic alternatives, including partnerships or out-licensing, to advance these assets with appropriate funding while conserving cash. 3. Operating model . The Company is transitioning to a virtual operating model to minimize burn while prioritizing its clinical-stage program(s). Workforce reductions include the elimination of the Chief Executive Officer, President, and Chief Operating Officer position
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Protagenic Therapeutics, Inc. Date: August 13, 2025 By: /s/ Alexander K. Arrow Alexander K. Arrow Chief Financial Officer